Dermatofibroma medical therapy: Difference between revisions
Jump to navigation
Jump to search
m (Bot: Removing from Primary care) |
|||
| (One intermediate revision by one other user not shown) | |||
| Line 7: | Line 7: | ||
==Medical Therapy== | ==Medical Therapy== | ||
Dermatofibromas are [[benign]] and no treatment is generally needed. | *Dermatofibromas are [[benign]] and no treatment is generally needed. | ||
**If the treatment is needed, [[local]] [[excision]] is the mainstay one.<ref name="JakobiecTu2017">{{cite journal|last1=Jakobiec|first1=Frederick A.|last2=Tu|first2=Yufei|last3=Zakka|first3=Fouad R.|last4=Tong|first4=Arthur K.F.|title=Dermatofibroma of the eyelid with monster cells|journal=Survey of Ophthalmology|volume=62|issue=4|year=2017|pages=533–540|issn=00396257|doi=10.1016/j.survophthal.2016.12.007}}</ref> | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
| Line 15: | Line 15: | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
| |||
[[Category:Medicine]] | [[Category:Medicine]] | ||
[[Category:Oncology]] | [[Category:Oncology]] | ||
[[Category:Up-To-Date | [[Category:Up-To-Date]] | ||
[[Category:Dermatology]] | [[Category:Dermatology]] | ||
Latest revision as of 21:18, 29 July 2020
|
Dermatofibroma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Dermatofibroma medical therapy On the Web |
|
American Roentgen Ray Society Images of Dermatofibroma medical therapy |
|
Risk calculators and risk factors for Dermatofibroma medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1], Associate Editor(s)-in-Chief: Homa Najafi, M.D.[2]
Overview
There is no pharmacologic medical therapy for dermatofibromas . Dermatofibromas are benign and no treatment is generally needed. If the treatment is needed, local excision is the mainstay one.
Medical Therapy
- Dermatofibromas are benign and no treatment is generally needed.
References
- ↑ Jakobiec, Frederick A.; Tu, Yufei; Zakka, Fouad R.; Tong, Arthur K.F. (2017). "Dermatofibroma of the eyelid with monster cells". Survey of Ophthalmology. 62 (4): 533–540. doi:10.1016/j.survophthal.2016.12.007. ISSN 0039-6257.